Completed PHASE3 INTERVENTIONAL 2-arm NCT03928743

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis (BE MOBILE 2)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

Sponsor: UCB Biopharma SRL

Conditions Ankylosing Spondylitis

Interventions Bimekizumab Placebo

Updated 41 times since 2019 Last updated: Dec 5, 2025 Started: Apr 25, 2019 Primary completion: Sep 3, 2021 Completion: Aug 8, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Ankylosing Spondylitis and is currently completed. UCB Biopharma SRL leads this study, which shows 41 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

41 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
Nov 2024 — Sep 2025 [monthly]

Completed PHASE3
Sep 2024 — Nov 2024 [monthly]

Completed PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 36 earlier versions

Jul 2024 — Aug 2024 [monthly]

Completed PHASE3
Jun 2024 — Jul 2024 [monthly]

Completed PHASE3
Mar 2024 — Jun 2024 [monthly]

Completed PHASE3
Mar 2023 — Mar 2024 [monthly]

Completed PHASE3
Sep 2022 — Mar 2023 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE3
Mar 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE3
Feb 2022 — Mar 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Active Not Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE3
Nov 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE3
Oct 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE3
Sep 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE3
Jun 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2021 — Jun 2021 [monthly]

Recruiting PHASE3
Apr 2021 — May 2021 [monthly]

Recruiting PHASE3
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE3
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE3
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE3
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Sep 2020 — Dec 2020 [monthly]

Recruiting PHASE3
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE3
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE3

Status: Suspended → Recruiting
May 2020 — Jul 2020 [monthly]

Suspended PHASE3

Status: Recruiting → Suspended
Apr 2020 — May 2020 [monthly]

Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE3
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE3
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE3
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE3
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE3
Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Jun 2019 — Aug 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
May 2019 — Jun 2019 [monthly]

Not Yet Recruiting PHASE3

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Biopharma SRL

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Beijing, China , Berlin, Germany , Boulogne-Billancourt, France , Brno, Czechia , Brussels, Belgium , Chengdu, China , Chūōku, Japan and 62 more locations